These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
415 related articles for article (PubMed ID: 19210710)
21. Clinical monograph for drug formulary review: erectile dysfunction agents. Campbell HE J Manag Care Pharm; 2005 Mar; 11(2):151-71. PubMed ID: 15766322 [TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of medium and long-term tadalafil use in spinal cord patients with erectile dysfunction. Lombardi G; Macchiarella A; Cecconi F; Del Popolo G J Sex Med; 2009 Feb; 6(2):535-43. PubMed ID: 19138363 [TBL] [Abstract][Full Text] [Related]
23. Psychosocial outcomes and drug attributes affecting treatment choice in men receiving sildenafil citrate and tadalafil for the treatment of erectile dysfunction: results of a multicenter, randomized, open-label, crossover study. Dean J; Hackett GI; Gentile V; Pirozzi-Farina F; Rosen RC; Zhao Y; Warner MR; Beardsworth A J Sex Med; 2006 Jul; 3(4):650-661. PubMed ID: 16839321 [TBL] [Abstract][Full Text] [Related]
24. A comparison of different oral therapies versus no treatment for erectile dysfunction in 196 radical nerve-sparing radical prostatectomy patients. Natali A; Masieri L; Lanciotti M; Giancane S; Vignolini G; Carini M; Serni S Int J Impot Res; 2015; 27(1):1-5. PubMed ID: 25056808 [TBL] [Abstract][Full Text] [Related]
25. The ENDOTRIAL study: a spontaneous, open-label, randomized, multicenter, crossover study on the efficacy of sildenafil, tadalafil, and vardenafil in the treatment of erectile dysfunction. Jannini EA; Isidori AM; Gravina GL; Aversa A; Balercia G; Bocchio M; Boscaro M; Carani C; Corona G; Fabbri A; Foresta C; Forti G; Francavilla S; Granata AR; Maggi M; Mansani R; Palego P; Spera G; Vetri M; Lenzi A; J Sex Med; 2009 Sep; 6(9):2547-60. PubMed ID: 19570039 [TBL] [Abstract][Full Text] [Related]
26. [Comparative study for the treatment of erectile dysfunction with sildenafil and vardenafil--multi-centric research in Nagano City]. Toshiyasu A; Tetsuya I; Katsurou T; Masahisa W; Takashi T; Naonori S; Youko U; Toshikazu O; Shuji N; Michinori M; Takeshi N; Takayuki K; Tatsuo N; Tomio S; Makoto A; Takamizawa A; Nihon Hinyokika Gakkai Zasshi; 2009 Jan; 100(1):1-6. PubMed ID: 19198222 [TBL] [Abstract][Full Text] [Related]
28. Effectiveness of Phosphodiesterase 5 Inhibitors in the Treatment of Erectile Dysfunction in Patients with Spinal Cord Trauma: Systematic Review and Meta-Analysis. García-Perdomo HA; Echeverría-García F; Tobías A Urol Int; 2017; 98(2):198-204. PubMed ID: 27509143 [TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of vardenafil in men with erectile dysfunction caused by spinal cord injury. Giuliano F; Rubio-Aurioles E; Kennelly M; Montorsi F; Kim ED; Finkbeiner AE; Pommerville PJ; Colopy MW; Wilkins HJ; Wachs BH; Neurology; 2006 Jan; 66(2):210-6. PubMed ID: 16434656 [TBL] [Abstract][Full Text] [Related]
32. Factors associated with preference for sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy: post hoc analysis of data from a multicentre, randomized, open-label, crossover study. Eardley I; Montorsi F; Jackson G; Mirone V; Chan ML; Loughney K; Vail GM; Beardsworth A BJU Int; 2007 Jul; 100(1):122-9. PubMed ID: 17552960 [TBL] [Abstract][Full Text] [Related]
33. Up-titration of vardena fi l dose from 10 mg to 20 mg improved erectile function in men with spinal cord injury. Kimoto Y; Sakamoto S; Fujikawa K; Tachibana T; Yamamoto N; Otani T Int J Urol; 2006 Nov; 13(11):1428-33. PubMed ID: 17083398 [TBL] [Abstract][Full Text] [Related]
34. Nebivolol potentiates the efficacy of PDE5 inhibitors to relax corpus cavernosum and penile arteries from diabetic patients by enhancing the NO/cGMP pathway. Martínez-Salamanca JI; La Fuente JM; Cardoso J; Fernández A; Cuevas P; Wright HM; Angulo J J Sex Med; 2014 May; 11(5):1182-92. PubMed ID: 24877179 [TBL] [Abstract][Full Text] [Related]
35. Prescribing all phosphodiesterase 5 inhibitors to a patient with erectile dysfunction--a realistic and feasible option in everyday clinical practice--outcomes of a simple treatment regime. Ströberg P; Hedelin H; Ljunggren C Eur Urol; 2006 May; 49(5):900-7; discussion 907. PubMed ID: 16564126 [TBL] [Abstract][Full Text] [Related]
36. The POTENT I randomized trial: efficacy and safety of an orodispersible vardenafil formulation for the treatment of erectile dysfunction. Sperling H; Debruyne F; Boermans A; Beneke M; Ulbrich E; Ewald S J Sex Med; 2010 Apr; 7(4 Pt 1):1497-507. PubMed ID: 20233275 [TBL] [Abstract][Full Text] [Related]
37. Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction? Doggrell S Int J Impot Res; 2007; 19(3):281-95. PubMed ID: 17183346 [TBL] [Abstract][Full Text] [Related]
38. New treatment options for erectile dysfunction in patients with diabetes mellitus. Basu A; Ryder RE Drugs; 2004; 64(23):2667-88. PubMed ID: 15537369 [TBL] [Abstract][Full Text] [Related]
39. Real-life safety and efficacy of vardenafil in the treatment of erectile dysfunction-results from 30,010 U.S. patients. Cheng E J Sex Med; 2007 Mar; 4(2):432-9. PubMed ID: 17087804 [TBL] [Abstract][Full Text] [Related]
40. Vardenafil improves erectile function in men with erectile dysfunction irrespective of disease severity and disease classification. Donatucci C; Eardley I; Buvat J; Gittelman M; Kell P; Segerson T; Homering M; Montorsi F; J Sex Med; 2004 Nov; 1(3):301-9. PubMed ID: 16422960 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]